10 results were returned
Today the Court of Justice of the European Union (CJEU) handed down its decision in the Royalty Pharma case concerning the interpretation of Art. 3 a of Regulation EC 469/2009 on Supplementary Protection Certificates ...
In Illumina v Latvia MGI Tech (‘MGI’)  EWHC 57 (Pat), Birss J (as he then was) has handed down a 520 paragraph judgment providing some helpful practical guidance in respect of several issues that commonly arise in ...
Our international IP team are thrilled to announce the promotion of 3 new partners today. These promotions reflect our ongoing commitment to ensure the diversity of our team develops to reflect the rich pool of talent ...
The Patents Court has considered enablement in relation to anticipation of a claimed monoclonal antibody invention by prior art, and held the patent was invalid for lack of novelty; it was also obvious for lack of ...
The Patents Court has rejected a public interest defence and granted an injunction, following a finding that patents for a medical device were valid and infringed.
The Supreme Court has held that two patents for a transgenic mouse used for the development of human antibodies were invalid for insufficiency.
By resolution dated February 10, 2021 the Italian Medicines Agency (AIFA) clarified the criteria for generic medicinal products to be inserted in the Substitution List (“Lista di Trasparenza”).
This decision follows the recent trend for the ECJ to give more straightforward interpretations of the SPC Regulation, providing certainty for users of the system.
We are delighted to announce that we received four prestigious awards at the Who’s Who Legal Awards 2020 held virtually in November.